HENDERA
831152
Hengerda New Materials
300946
Fujian Nebula Electronics.,Ltd
300648
4
Cubic Digital Technology
300344
5
HNAC Technology
300490
US Stock MarketDetailed Quotes
RSLS ReShape Lifesciences
- 1.0999
- -1.2301-52.79%
Trading Feb 18 15:54 ET
802.91KMarket Cap-0.11P/E (TTM)
1.2000High1.0100Low5.67MVolume1.1800Open2.3300Pre Close6.28MTurnover819.65%Turnover RatioLossP/E (Static)729.98KShares29.000052wk High0.54P/B761.31KFloat Cap1.010052wk Low--Dividend TTM692.17KShs Float4647888000.0000Historical High--Div YieldTTM8.16%Amplitude1.0100Historical Low1.1070Avg Price1Lot Size
Trending Stocks
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
ReShape Lifesciences Stock Forum
5 MINUTES AGO, 8:31 AM EST
VIA GLOBENEWSWIRE
ReShape Lifesciences (RSLS) reported Q3 2024 financial results, showing revenue growth of 16.6% over Q2 2024 and 6.4% year-over-year to $2.3 million.
The company achieved a 40.6% reduction in operating expenses for the first nine months of 2024 compared to 2023.
Gross profit margin improved to 62.8% in Q3 2024.
The company entered into a merger agreement with Vyome Therapeutics and an asset purchase agreement with Biorad Medisys for $5.16 million.
ReSha...
ReShape Lifesciences: Entered Into Merger Agreement With Vyome Therapeutics & Asset Purchase Agreement With Biorad Medisys
4 mins ago
ReShape Lifesciences® Receives Health Canada Approval for Its Next-Generation Lap-Band® 2.0 Flex
No comment yet